As senescence markers such as SA-beta-gal, reduced Ki67 or p16INK4a expression can be readily monitored in tissue samples, we suggest that advancement to androgen-refractory cancer may be clinically assessed by reduction or loss of these markers in AD-treated patient tumors. Here, CDKN2A is linked to Alzheimer disease.